A phase I and pharmacologic study of the proteosome inhibitor PS-341 [bortezomib] in patients with advanced solid tumors and B-cell lymphoproliferative disorders

Trial Profile

A phase I and pharmacologic study of the proteosome inhibitor PS-341 [bortezomib] in patients with advanced solid tumors and B-cell lymphoproliferative disorders

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2011

At a glance

  • Drugs Bortezomib (Primary)
  • Indications B cell lymphoma; Leukaemia; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top